Global /United States /Healthcare /Biotechnology /SABS

SAB Biotherapeutics, Inc.

SABS

• NASDAQ: SABS • Delayed

3.50USD -1%

As of 13 June 2026, SAB Biotherapeutics, Inc. has a market cap of $245.61M USD, ranking #19818 globally and #3265 in the United States. It ranks #1780 in the Healthcare sector, and #343 in the Biotechnology industry.

Global Rank

19818

Country Rank

3265

Sector Rank

1780

Industry Rank

343

Key Stats

Market Cap

$245.61MUSD

Enterprise Value

$153.92MUSD

EBITDA (TTM)

-$45.87MUSD

Net Income (TTM)

$4.26MUSD

PB Ratio

1.1

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Samuel Reich open_in_new

Employees

Founded

2014

Website

sab.bio open_in_new

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1%	-12%	-9.2%	-21%	16%	-6.6%	95%	-61%	-96%

News

SABS Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	SABS SAB Biotherapeutics Inc ISIN: US78397T2024 Shares Out.: Shares Outstanding: 76.464M¹ Shares Float: 57.078M² TV: TradingView: NASDAQ: SABS SA: Stock Analysis: NASDAQ: SABS YF: Yahoo Finance: SABS GF: Google Finance: NASDAQ: SABS NQ: NASDAQ: SABS BA: Barron's: SABS MS: Morningstar: XNAS: SABS	3.50 USD	TV: TradingView: NASDAQ: SABS SA: Stock Analysis: NASDAQ: SABS YF: Yahoo Finance: SABS GF: Google Finance: NASDAQ: SABS NQ: NASDAQ: SABS BA: Barron's: SABS MS: Morningstar: XNAS: SABS

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 74K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 65K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 11K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 11K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 10K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 7K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 19K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 18K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 17K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 17K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 11K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 10K%	-	Germany

chevron_leftBack